Replies to post #137656 on Biotech Values

[oc631]

Does anyone feel if one of the two drugs that make-up Qnexa wasn't generic the advisory panel would have voted differently?

Considering phentermine and topiramate are currently being used widely off-label. Price and finding the right doctor seem to be the only limiting factors. Cheap and easy access, along with increasing public awareness of off-label use, might force the FDA's hand towards approval instead of prudently asking for further testing. The REM strategy beats unchecked usage in an off-label market growing exponentially.

[hptaxis]

Will VVUS do a secondary? It seems reasonable.

[DewDiligence]

Does anyone feel if one of the two drugs that make-up Qnexa wasn't generic the advisory panel would have voted differently?

If Qnexa were a novel drug, I think the panel’s sentiment would have been considerably different and might well have produced a plurality of negative votes.